The Association of Registered Trichologists

01/08/2024

🦂 Black Henna tattoos... there's a sting in the tail. - https://mailchi.mp/trichocare/emma-chats-with-paul-falltrick-6228881

⚠ In the UK black henna tattoos are illegal, and outside the UK there’s confusion about the legislation.

⚠ The excessively high levels of PPD in black henna is dangerous.

⚠ There is a strong link between over-exposing the body to PPD and allergic reactions.

⚠ People will have no idea of the PPD levels they’ve encountered.

⚠ They designed to last a few weeks & your client might not have a reaction for 10 years or more.

24/01/2024

Two sessions:
Monday 11 March 2024
The Trichology Centre, Margaret Powell House Milton Keynes, MK9 3BN
The morning session (10.30am registration–1pm) is for
anyone wishing to know just a little more about Trichology as a profession–an introduction to Trichology with leading experts in the field of Clinical Diagnosis. The cost is £65.00 per session, limited to six delegates only.
The afternoon session (1pm–to 5pm) is for students currently studying Trichology, or graduates, who want some practical experience in consultation techniques seeing clients at the Milton Keynes Trichology Community Foundation–a hands-on approach to understand a variety hair and scalp conditions. The cost is £65.00 per session, limited to six delegates only.

24/08/2022

Patients prefer shared decision-making regarding alopecia areata treatment.

Patients with alopecia areata preferred a shared decision-making model with their dermatologists in deciding treatment, according to a study by Sophia Reyes-Hadsall et al.

“Alopecia areata (AA) is an autoimmune disorder of hair loss with several therapeutic options that vary in efficacy and safety,” Reyes-Hadsall, BS, of the University of Miami Miller School of Medicine and the department of dermatology at Brigham and Women’s Hospital, and colleagues wrote in the brief report. “The complex nature of AA treatment decision-making is difficult for patients to navigate and increases reliance on their dermatologist’s guidance through shared decision-making (SDM) to make decisions that best align with their preferences.”

A cross-sectional web-based survey was sent to a sample of AA patients using the National Alopecia Areata Foundation’s list servs asking patient preferences when making treatment decisions, the patient’s perception of their most recent treatment decisions and how SDM impacted those decisions.

Of 1,074 patients who completed the survey, 46.8% (n = 503) preferred to make the final treatment decision themselves after considering their dermatologist’s opinion and 65.9% (n = 708) reported making their last treatment decision with their physician.

Patients who made their last treatment decisions completely on their own comprised 26.4% (n = 283) of the group, while 7.7% (n = 83) left the decision solely to their dermatologist.

For those patients who said they preferred SDM, physicians asking which treatment option the patient preferred (45.9% completely or strongly agreed) and physicians explaining the advantages and disadvantages of treatment options (44% completely or strongly agreed) were the components most identified as being part of the patients’ last AA treatment.

Decisional regret was reported least in those who were taking Janus kinase inhibitors — with 74.5% being satisfied with that choice — followed by biologics (60% satisfied) and the decision not to treat (55.9% satisfied).

Approximately half of patients (n = 559; 52%) felt they made the right decision. Also, 50.8% (n = 546) said they would make the same choice again.

“Patients preferred to make AA treatment decisions using SDM, which was associated with less decisional regret,” the authors wrote. “Regardless of treatment choice, implementing components of SDM may help improve the quality of treatment decisions patients make by allowing them to choose treatment options that align with their values and preferences.

04/01/2022

Looking for a new role in trichology? Are you passionate about education? Find out more:

"),r.close()),!r)throw Error("base not supported");var a=r.createElement("base");a.href=n,r.getElementsByTagName("head")[0].appendChild(a);var i=r.createElement("a");return i.href=t,i.href}finally{e&&e.parentNode.removeChild(e)}}());var l=i(t||""),f=function(){if(!("defineProperties"in Object))retur...

25/12/2021

19/12/2021

New Year, new job? Apply now: https://buff.ly/31RGsY7

17/12/2021

New Year, looking for a fresh start? Find out more: https://buff.ly/31RGsY7

11/12/2021

Trichocare Education is hiring ... find out more: https://buff.ly/31RGsY7

10/12/2021

Looking for a related job role? This could be the one: https://buff.ly/31RGsY7

05/09/2021

Congratulations to Consultant Trichologist and our member, Demi Griffiths ART, for her achievements as a Trichologist. TrichoCare Midlands Trichology

06/07/2021

The first medicine for finding out if you may be allergic to hair colour (PPD) a potentially very valuable tool for Trichologists.

Colourstart is designed to find out if your client might be allergic to one of the ingredients, called PPD, that is found in most hair colorants. If the client takes the test and it is positive (meaning that they show a reaction) you should not use hair colour on them.

https://buff.ly/3Alwuv4

Colourstart Test 65mcg Cutaneous patch. Contains p-phenylenediamine (PPD). A screening test for allergy to hair colour (PPD). Always read the label.

28/07/2020

Beautiful image 🖤